Pharmaceutical Intermediates Industry Report 2025: Market to worth $82.70 Billion by 2032 - Driven by Surge in Global Pharma Expenditure - BioSpace

According to Coherent Market Insights(CMI), the global pharmaceutical intermediates market size is forecast to totalUSD 47.30 Bn in 2025 and USD 82.70 Bn by 2032.

Global demand for pharmaceuticalintermediates is anticipated to increase at a CAGR of 8.3% between 2025 and2032, owing to rising prevalence of chronic diseases and increasing spending onpharmaceuticals.

By intermediate type, bulkintermediate segment is expected to generate a revenue of around USD 32.11 Bnin 2025.

Based on application, anti-inflammatorydrugs segment is projected to reach USD 13.38 Bn by 2025, driven by increasingprevalence of inflammatory and pain-related diseases.

By end user, CMOs segment isanticipated to account for more than one-third of the global pharmaceuticalintermediates market share in 2025.

As per Coherent Market Insights’latest pharmaceutical intermediates market analysis, North America is set to retainits dominance, accounting for nearly two-fifths of the global industry share in2025.

Asia Pacific, led by China and India,is expected to exhibit fastest growth during the assessment period. This can beattributed to rising prevalence of chronic diseases and surging demand foraffordable generic medications.

Request Sample Pages: https://www.coherentmarketinsights.com/insight/request-sample/6740

Increasing PharmaceuticalSpending Boosting Market Growth

Coherent Market Insights’ pharmaceuticalintermediates market report highlights prominent factors driving the industry’sgrowth. Increasing pharmaceutical expenditure globally is one such growthdriver.

Pharmaceutical spending is increasingsignificantly across nations like the United States, Germany, France, andIndia. This is due to growing geriatric population and rising prevalence ofchronic diseases like diabetes, cancer, and cardiovascular conditions.

For instance, according to the Centersfor Medicare & Medicaid Services (CMS), U.S. retail prescription drugexpenditures totaled a massive valuation of US$ 449.7 billion in 2023. This surgein pharmaceutical spending is expected to drive demand for pharmaceuticalintermediates.

Pharmaceutical intermediates areessential compounds used in the production of active pharmaceutical ingredients(APIs). Thus, an increase in demand for APIs and medications will directly leadto higher sales of pharmaceutical intermediates.

Presence of Stringent Regulations LimitingIndustry Growth

The future pharmaceuticalintermediates market outlook looks optimistic, supported by rising incidence ofchronic diseases and increasing demand for pharmaceuticals. However, strictregulatory requirements are limiting market growth to some extent.

Pharmaceutical intermediates aresubject to strict regulations as well as quality standards from regulatorybodies like the FDA and EMA. Compliance with these regulations often requiressubstantial costs and can lead to delays in approvals, which are expected tohinder market expansion in the coming years.

Growing Demand for Generic Drugs toCreate Lucrative Opportunities for Players

Generic drugs have become affordabletreatment options in the modern world, especially for managing the burden ofchronic diseases. They are gaining traction among both physicians and patientsdue to their cost-effectiveness, combined with comparable efficacy and safetyto original drugs.

Rising interest in generic drugsglobally is expected to create lucrative growth prospects for pharmaceuticalintermediate manufacturers. This is because these intermediates are vital forproducing generic drugs.

Increasing government support willalso create a conducive environment for pharmaceutical intermediates marketgrowth. Many nations are introducing new policies and laws to promote domesticpharmaceutical manufacturing.

For instance, in May 2025, the UnitedStates President Donald Trump signed an executive order to boost domesticproduction of prescription drugs. Such initiatives are expected to unlock newrevenue generation opportunities for pharmaceutical intermediate companies.

Ask for Customization Report: https://www.coherentmarketinsights.com/insight/request-customization/6740

Emerging Pharmaceutical IntermediatesMarket Trends

Emergence of new drugs is expected toprovide a strong impetus for the growth of pharmaceutical intermediates market.Pharmaceutical companies are increasing their R&D spending to developinnovative drugs, especially in oncology, neurology, and rare diseases. Thiswill uplift the demand for specialty and high-purity pharmaceuticalintermediates.

Rapid expansion of biopharmaceutical and biosimilar sectorsis expected to create new growth avenues for industry players. These biologicsoften require different types of intermediates, encouraging innovation inpharmaceutical intermediate production.

Advancements in pharmaceutical intermediate manufacturingtechnologies are helping companies to improve efficiency, lower costs, andreduce environmental impact. These innovations are expected to support expansionof the target industry.

Sustainability is taking the center stage in pharmaceuticalintermediates industry, driven by regulatory pressures and growingenvironmental awareness. As a result, companies are employing environmentallyfriendly and sustainable practices in the production of pharmaceuticalintermediates.

Increasing trend of pharmaceutical outsourcing will alsobenefit the target market. Leading pharmaceutical companies are increasinglyoutsourcing the manufacturing of intermediates to contract manufacturingorganizations (CMOs) to streamline processes and reduce costs.

Analyst’s View

“The global pharmaceutical intermediates market is setto experience robust growth, owing to rising prevalence of chronic diseases,increasing pharmaceutical spending, and growing popularity of generic drugs,” said senior analyst Vipul Patil. “Onthe other hand, high implementation of stringent regulations might slow downmarket growth to some extent.”

Current Events and Their Impact on the PharmaceuticalIntermediates Market

Event

Description and Impact

Rising Demand for Pharmaceuticals

Advancements in Synthetic Biology

Increasing Research and Development Activities

Competitor Insights

Key companies in pharmaceuticalintermediates market research report:

- Borregaard AS

- Actylis

- Sudarshan Pharma

- Evonik

- Midas Pharma GmbH

- A.R. Life Science

- Sanofi

- Chiracon GmbH

- Saurav Chemicals Ltd.

- Lianhetech

- BASF SE

- Lifechem Pharma

- Lonza

- Chemcon Speciality ChemicalsLimited

- LANXESS

- Modepro India Pvt. Ltd.

- Sarex

Get Up to 25% Discount on the US Tariff Impact Analysis Report: https://www.coherentmarketinsights.com/insight/buy-now/6740

Key Developments

In May 2024, BASF expanded its biomassbalance offering for selected chemical intermediates, including polytetrahydrofuran(PolyTHF), BMBCert 1,4-butanediol (BDO), and 3-(dimethylamino) proylamine(DMAPA).

In October 2024, Astal Laboratoriesacquired Shree Venus Health Sciences’ pharmaceutical intermediatesmanufacturing plant in Karnataka, India.

In September 2024, Evonik officially openedits new facility for drying aqueous dispersion of EUDRAGIT polymers atDarmstadt. The new manufacturing facility is designed to help the company meetincreasing demand from pharmaceutical customers.

Browse More RelatedReports:

Global PharmaceuticalChemicals Market Size and Share Analysis (2025-2032)

High Potency ActivePharmaceutical Ingredients Market Size, Share, and Trend Analysis Report(2025-2032)

Active Pharmaceutical IngredientsMarket: Growth, Size, Share, and Trend (2025-2032)

Our Trusted Partners:Worldwide Market Reports, Coherent MI, Stratagem Market Insights

Get Recent News:https://www.coherentmarketinsights.com/news

About Us:

Coherent Market Insights leads into data and analytics,audience measurement, consumer behaviors, and market trend analysis. Fromshorter dispatch to in-depth insights, CMI has exceled in offering research,analytics, and consumer-focused shifts for nearly a decade. With cutting-edgesyndicated tools and custom-made research services, we empower businesses tomove in the direction of growth. We are multifunctional in our work scope andhave 450+ seasoned consultants, analysts, and researchers across 26+ industriesspread out in 32+ countries.

Contact Us:

Mr. ShahSenior Client Partner – Business DevelopmentCoherent Market Insights

Phone:

US: + 12524771362

UK: +442039578553

AUS:+61-2-4786-0457

India: +91-848-285-0837

Email: [email protected]

Website: https://www.coherentmarketinsights.comFor Latest Update Follow Us:LinkedIn | Facebook | Twitter